BRCA1 and ovarian cancer: To test if PCGT and MESC methylation changes are also present in cells which are not immediately involved in carcinogenesis we studied white blood cell DNA from women who carry BRCA1 mutations and who are therefore at an 80% lifetime risk of developing breast and/or ovarian cancer.